Multicenter Clinical Performance Study to evaluate Plasma-based RAS Gene Mutation Testing using OncoBEAM RAS CRC assay (LS52R) of Patients having Progressive or Recurrent Colorectal Cancer

ABSTRACT: Primary outcome(s): Overall percent agreement (OPA) of both KRAS and NRAS gene exon 2, 3 and 4 mutations between Plasma RAS testing and Reference method

DISEASE(S): Colorectal Cancer

PROVIDER: 2638296 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR